AstraZeneca plc (LON:AZN) Alexion, AstraZeneca Rare Disease, has completed a definitive purchase and licence agreement for a portfolio of preclinical rare disease gene therapy programmes and enabling technologies from Pfizer..
AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 3.6% according to Deutsche.Deutsche set a target price of 11,000 GBX for the company, which when compared to the..
AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 27.2% according to Barclays.Barclays set a target price of 13,500 GBX for the company, which when compared to the..
AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 3.8% according to Deutsche.Deutsche set a target price of 11,000 GBX for the company, which when compared to the..
AstraZeneca plc (LON:AZN) Alexion has announced that it has entered a definitive purchase and licence agreement for a portfolio of preclinical gene therapy programmes and enabling technologies from Pfizer Inc...
AstraZeneca plc (LON:AZN) has announced datopotamab deruxtecan met dual primary endpoint of progression-free survival in patients with advanced non-small cell lung cancer in TROPION-Lung01 Phase III trial. Positive high-level results..
The US Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) has voted unanimously 21 to 0 that AstraZeneca and Sanofi’s nirsevimab has a favourable benefit risk profile for..
AstraZeneca plc (LON:AZN) Imfinzi plus Lynparza and Imfinzi alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy. Positive high-level results from the DUO-E Phase III..
AstraZeneca PLC (LON:AZN) has announced that Anna Manz has been appointed as a Non-Executive Director and a member of the Audit Committee with effect from 1 September 2023. Anna is..
Positive high-level results from the FLAURA2 Phase III trial showed AstraZeneca plc (LON:AZN) Tagrisso (osimertinib) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival..
AstraZeneca’s Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death, hospitalisation for heart failure (hHF) and urgent heart failure (HF) visits in adults with HF. The approval..
AstraZeneca plc (LON:AZN) has announced that the Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has recognised a favourable benefit risk profile for AstraZeneca and MSD’s Lynparza (olaparib)..
AstraZeneca plc (LON:AZN), Swedish Orphan Biovitrum AB (publ) (Sobi) and Sanofi have updated and simplified their contractual arrangements relating to the development and commercialisation of nirsevimab in the US. Given..
AstraZeneca Plc (LON:AZN) today provided an results from an analysis of the ongoing DESTINY-PanTumor02 Phase II trial. Positive high-level results from an analysis of the ongoing DESTINY-PanTumor02 Phase II trial..
AstraZeneca plc (LON:AZN) has completed the acquisition of Neogene Therapeutics Inc., a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies (TCR-Ts). Neogene will..
AstraZeneca plc (LON:AZN) and MSD’s Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone has been approved in the European Union for the treatment of metastatic castration-resistant prostate cancer..
AstraZeneca plc (LON:AZN) and MSD today announced that the US Food and Drug Administration (FDA) has informed AstraZeneca that it will extend the Prescription Drug User Fee Act (PDUFA) date..
AstraZeneca plc (LON:AZN) has announced the sale of its West Chester site in Ohio, US, to National Resilience, Inc., a technology-focused manufacturing company dedicated to broadening access to complex medicines...
AstraZeneca plc (LON:AZN) Imfinzi (durvalumab) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line treatment of adult patients with unresectable or metastatic biliary tract cancer..
AstraZeneca plc (LON:AZN) Imfinzi (durvalumab) in combination with Imjudo (tremelimumab) plus platinum-based chemotherapy has been approved in the US for the treatment of adult patients with Stage IV (metastatic) non-small..
